Literature DB >> 19915218

Statin therapy with ezetimibe or niacin in high-risk patients.

John J P Kastelein, Michiel L Bots.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19915218     DOI： 10.1056/NEJMe0908841

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Strategies to achieve target LDL levels.

Authors:  Alan Chait
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

Review 2.  Treatment of familial hypercholesterolemia: is there a need beyond statin therapy?

Authors:  Anna Raper; Daniel M Kolansky; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

3.  Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia.

Authors:  Yuqing Zhang; Rusheng Zhang; Yong Li; Guoping He; Dingguo Zhang; Fumin Zhang
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

Review 4.  What combination therapy with a statin, if any, would you recommend?

Authors:  Carlos A Dujovne; Craig D Williams; Matthew K Ito
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

5.  Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe.

Authors:  Philip Schwab; Anthony Louder; Yong Li; Rajiv Mallick; Harold Bays
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 3.923

6.  Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Authors:  Peter Willeit; Lena Tschiderer; Michael J Sweeting; Simon G Thompson; Matthias W Lorenz; Elias Allara; Kathrin Reuber; Lisa Seekircher; Lu Gao; Ximing Liao; Eva Lonn; Hertzel C Gerstein; Salim Yusuf; Frank P Brouwers; Folkert W Asselbergs; Wiek van Gilst; Sigmund A Anderssen; Diederick E Grobbee; John J P Kastelein; Frank L J Visseren; George Ntaios; Apostolos I Hatzitolios; Christos Savopoulos; Pythia T Nieuwkerk; Erik Stroes; Matthew Walters; Peter Higgins; Jesse Dawson; Paolo Gresele; Giuseppe Guglielmini; Rino Migliacci; Marat Ezhov; Maya Safarova; Tatyana Balakhonova; Eiichi Sato; Mayuko Amaha; Tsukasa Nakamura; Kostas Kapellas; Lisa M Jamieson; Michael Skilton; James A Blumenthal; Alan Hinderliter; Andrew Sherwood; Patrick J Smith; Michiel A van Agtmael; Peter Reiss; Marit G A van Vonderen; Stefan Kiechl; Gerhard Klingenschmid; Matthias Sitzer; Coen D A Stehouwer; Heiko Uthoff; Zhi-Yong Zou; Ana R Cunha; Mario F Neves; Miles D Witham; Hyun-Woong Park; Moo-Sik Lee; Jang-Ho Bae; Enrique Bernal; Kristian Wachtell; Sverre E Kjeldsen; Michael H Olsen; David Preiss; Naveed Sattar; Edith Beishuizen; Menno V Huisman; Mark A Espeland; Caroline Schmidt; Stefan Agewall; Ercan Ok; Gülay Aşçi; Eric de Groot; Muriel P C Grooteman; Peter J Blankestijn; Michiel L Bots
Journal:  Circulation       Date:  2020-06-17       Impact factor: 29.690

Review 7.  Effects of niacin on atherosclerosis and vascular function.

Authors:  Neil Ruparelia; Janet E Digby; Robin P Choudhury
Journal:  Curr Opin Cardiol       Date:  2011-01       Impact factor: 2.161

8.  Treatment of dyslipidemia in the elderly.

Authors:  Hong Shao; Li-Quan Chen; Jun Xu
Journal:  J Geriatr Cardiol       Date:  2011-03       Impact factor: 3.327

9.  Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.

Authors:  Natale Vazzana; Antonina Ganci; Angelo Baldassare Cefalù; Stefano Lattanzio; Davide Noto; Nicole Santoro; Raoul Saggini; Luca Puccetti; Maurizio Averna; Giovanni Davì
Journal:  J Am Heart Assoc       Date:  2013-04-04       Impact factor: 5.501

Review 10.  Ezetimibe therapy: mechanism of action and clinical update.

Authors:  Binh An P Phan; Thomas D Dayspring; Peter P Toth
Journal:  Vasc Health Risk Manag       Date:  2012-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.